Ventyx Biosciences Inc (VTYX) USD0.0001

- Add to watchlist
- This stock can be held in a




Business summary
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of small molecule product candidates to address a range of inflammatory diseases with significant unmet need. Its pipeline includes VTX958, VTX002, and VTX2735 and VTX3232 (NLRP3 Inhibitor Portfolio). Its lead product candidate, VTX958, is an oral, selective allosteric tyrosine kinase type 2 (TYK2) inhibitor to address a range of immune-mediated diseases, such as psoriasis, Crohns disease, psoriatic arthritis and lupus. VTX958 is designed to selectively inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms. It is developing VTX002, an oral, selective sphingosine 1 phosphate receptor 1 (S1P1R) modulator for the treatment of ulcerative colitis (UC). Its lead NLRP3 inhibitor product candidate, VTX2735, is designed to treat systemic inflammatory diseases, such as cardiovascular, hepatic, renal and rheumatologic diseases.
Contact details
Important dates
General stock information
- Short code:
- VTYX
- ISIN:
- US92332V1070
- Market cap:
- $651.39 million
- Shares in issue:
- 50.85 million
- Sector:
- Pharmaceuticals
- Exchange:
- NASDAQ
- Country:
- United States
- Currency:
- US dollar
- Indices:
- n/a
Key personnel

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.